[New] Cloud Backups Just Got Simpler — Duplicator Cloud Eliminates Third-Party Storage
Explore scalable, affordable cloud storage plans with Duplicator Cloud and keep your site backups secure, organized, and accessible in one…
A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration
Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503
On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN).
[New] Cloud Backups Just Got Simpler — Duplicator Cloud Eliminates Third-Party Storage
A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration
Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503
On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN).
